Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux
Authors:
- Jennifer L. ChristensenJCJennifer L. Christensen
- Alfred M. AjamiAAAlfred M. Ajami
- Robert L. CapizziRCRobert L. Capizzi
- 1 March 2008
- journal article
- Published by Elsevier in Leukemia Research
- Vol. 32 (3) , 465-473
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- End points to establish the efficacy of new agents in the treatment of acute leukemiaBlood, 2006
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosisBlood, 2005
- Cyclosporin A Is a Broad-Spectrum Multidrug Resistance ModulatorClinical Cancer Research, 2005
- Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621Journal of Clinical Oncology, 2004
- Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)Journal of Clinical Oncology, 2004
- ATP-bound Topoisomerase II as a Target for Antitumor DrugsJournal of Biological Chemistry, 2001
- Dyes providing increased sensitivity in flow‐cytometric dye‐efflux assays for multidrug resistanceCytometry, 1995
- BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTERAnnual Review of Biochemistry, 1993
- Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources.Journal of Histochemistry & Cytochemistry, 1977